Payment overview · 2025
General Payments
$1,783.62
99 reported records · 12 companies
Healthcare provider profile · identity verified
Brandon M Thurow, MD
Allopathic & Osteopathic Physicians|Family Medicine · CONWAY, AR · NPI 1033346358
Verified facts
What the public records show
CMS Open Payments records show Brandon M Thurow, MD received $1,783.62 in general payments during 2025 across 99 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 400 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $546.27 | 30.6% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $290.51 | 16.3% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $250.85 | 14.1% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $227.25 | 12.7% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.95 | 8.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.82 | 4.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.34 | 3.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $55.96 | 3.1% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.47 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.53 | 1.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.27 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.40 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,776.97 | 98 |
| Education | $6.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $431.17 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $291.26 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $261.39 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $250.85 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $247.90 | 17 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $187.26 | 14 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $187.26 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $160.81 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $128.03 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.77 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $84.82 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.06 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.88 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $55.96 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.04 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $47.47 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $33.34 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.53 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $12.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 400 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
400 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 595 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 93 |
| Eliquis | Apixaban | 400 | 32 |
| Losartan Potassium | Losartan Potassium | 365 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 343 | 63 |
| Gabapentin | Gabapentin | 332 | 68 |
| Trazodone Hcl | Trazodone Hcl | 312 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 62 |
| Ezetimibe | Ezetimibe | 269 | 58 |
| Famotidine | Famotidine | 262 | 67 |
| Potassium Chloride | Potassium Chloride | 262 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 255 | 41 |
| Torsemide | Torsemide | 255 | 51 |
| Sertraline Hcl | Sertraline Hcl | 235 | 56 |
| Furosemide | Furosemide | 215 | 53 |
| Valsartan | Valsartan | 215 | 40 |
| Carvedilol | Carvedilol | 208 | 36 |
| Spironolactone | Spironolactone | 195 | 38 |
| Montelukast Sodium | Montelukast Sodium | 192 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 29 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 157 | 29 |
| Metformin Hcl | Metformin Hcl | 153 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 149 | 25 |
| Methenamine Hippurate | Methenamine Hippurate | 141 | 28 |
| Ozempic | Semaglutide | 141 | 21 |
| Celecoxib | Celecoxib | 136 | 31 |
| Donepezil Hcl | Donepezil Hcl | 135 | 30 |
| Terbinafine Hcl | Terbinafine Hcl | 130 | 70 |
| Buspirone Hcl | Buspirone Hcl | 129 | 33 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 123 | 23 |
| Omeprazole | Omeprazole | 116 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 54 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 102 | 19 |
| Memantine Hcl | Memantine Hcl | 102 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 25 |
| Probenecid | Probenecid | 92 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 40 |
| Methylprednisolone | Methylprednisolone | 87 | 70 |
| Mirtazapine | Mirtazapine | 87 | 27 |
| Jardiance | Empagliflozin | 86 | 13 |
| Entresto | Sacubitril/Valsartan | 85 | suppressed |
| Finasteride | Finasteride | 85 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 83 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 82 | 64 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 12 |
| Cefdinir | Cefdinir | 77 | 68 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 12 |
| Clonidine Hcl | Clonidine Hcl | 76 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 17 |
| Simvastatin | Simvastatin | 76 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 21 |
| Divalproex Sodium | Divalproex Sodium | 70 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 11 |
| Bupropion Hcl | Bupropion Hcl | 68 | 13 |
| Synthroid | Levothyroxine Sodium | 68 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 14 |
| Prednisone | Prednisone | 66 | 36 |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 65 | suppressed |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 56 |
| Lisinopril | Lisinopril | 63 | 13 |
| Lorazepam | Lorazepam | 63 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 46 |
| Megestrol Acetate | Megestrol Acetate | 62 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 18 |
| Fenofibrate | Fenofibrate | 61 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | 29 |
| Pregabalin | Pregabalin | 57 | 13 |
| Glimepiride | Glimepiride | 56 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 56 | 12 |
| Atenolol | Atenolol | 55 | 12 |
| Nifedipine Er | Nifedipine | 55 | 13 |
| Azithromycin | Azithromycin | 54 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 53 | 19 |
| Latanoprost | Latanoprost | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Sucralfate | Sucralfate | 50 | 16 |
| Primidone | Primidone | 49 | 11 |
| Dutasteride | Dutasteride | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 12 |
| Glipizide | Glipizide | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | 13 |
| Ondansetron Odt | Ondansetron | 47 | 32 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 28 |
| Levofloxacin | Levofloxacin | 43 | 39 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Baclofen | Baclofen | 41 | 17 |
| Kerendia | Finerenone | 41 | suppressed |
| Acarbose | Acarbose | 40 | suppressed |
| Sulindac | Sulindac | 39 | suppressed |
| Telmisartan | Telmisartan | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Novolin R | Insulin Regular, Human | 37 | suppressed |
| Temazepam | Temazepam | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Colchicine | Colchicine | 36 | 16 |
| Allopurinol | Allopurinol | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 17 |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 28 |
| Lidocaine Hcl | Lidocaine Hcl | 28 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 25 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Insulin Aspart | Insulin Aspart | 24 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 24 | 18 |
| Novolog | Insulin Aspart | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Admelog | Insulin Lispro | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 12 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 17 |
| Diazepam | Diazepam | 19 | suppressed |
| Ertapenem | Ertapenem Sodium | 19 | 14 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Digoxin | Digoxin | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Fentanyl | Fentanyl | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Zaleplon | Zaleplon | 17 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 16 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Tetrabenazine | Tetrabenazine | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,783.62 · 99 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, ZAVZPRET, ZENPEP, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error